New targeted therapies for renal cell carcinoma

Expert Opinion on Investigational Drugs

Volumn 20, Issue 7, 2011, Pages 933-945

  Fisher, Rosalie ^a   Pickering, Lisa ^a   Larkin, James ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

anti angiogenesis; chemotherapy; immunotherapy; mammalian target of rapamycin inhibitors; metastatic; P13K pathway inhibitors; renal cell carcinoma; tyrosine kinase inhibitors

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTINEOPLASTIC AGENT; AXITINIB; AZD 8055; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; DOVITINIB; EVEROLIMUS; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; INTERFERON; LINIFANIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MDX 1106; MK 2206; NVP BGT 226; OSI 027; PAZOPANIB; PERIFOSINE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SARACATINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; UNCLASSIFIED DRUG; XL 147; XL 765;

ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPHONIA; FATIGUE; GASTROINTESTINAL TUMOR; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOPTYSIS; HUMAN; HYPERTENSION; IC 50; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; LYMPHOMA; MELANOMA; METASTASIS; METASTATIC KIDNEY CARCINOMA; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PNEUMONIA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN DISEASE; SOLID TUMOR; STOMATITIS; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY NEOPLASMS; TREATMENT OUTCOME;

EID: 79958782573     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.577065     Document Type: Review

References (100)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75
3. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566-75 (Pubitemid 37509519)
4. Reuter VE. The pathology of renal epithelial neoplasms. Semin Oncol 2006;33:534-43 (Pubitemid 44511979)
5. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376-81 (Pubitemid 34441667)
6. Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 1983;10:422-30 (Pubitemid 14158611)
7. Yagoda A, Bander NH. Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 1989;44:338-45 (Pubitemid 20008357)
8. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96 (Pubitemid 34032623)
9. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005:CD001425
10. McDermott DF, GM, Signoretti S, Ghebremichael MS, et al. The high-dose aldesleukin 'SELECT' trial in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28:abstract 4514
11. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004 (Pubitemid 46646218)
12. Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-24 (Pubitemid 23293287)
13. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007;13:680s-684s
14. Kamura T, Sato S, Iwai K, et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000;97:10430-5
15. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-7
16. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5 (Pubitemid 29246458)
17. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87 (Pubitemid 41058349)
18. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998;58:226-31 (Pubitemid 28047059)
19. Ananth S, Knebelmann B, Gruning W, et al. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999;59:2210-16 (Pubitemid 29217687)
20. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22 (Pubitemid 47001784)
21. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983-5 (Pubitemid 32928669)
22. Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204
23. Porta C, Figlin RA. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3- kinase/Akt inhibitors. J Urol 2009;182:2569-77
24. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-64 (Pubitemid 41637985)
25. Averous J, Proud CG. When translation meets transformation: the mTOR story. Oncogene 2006;25:6423-35 (Pubitemid 44582286)
26. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14
27. van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 2010;16:3094-9
28. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12
29. Edgren M, Lennernas B, Larsson A, Nilsson S. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res 1999;19:869-73 (Pubitemid 29168347)
30. Sato K, Tsuchiya N, Sasaki R, et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 1999;90:874-9 (Pubitemid 29431367)
31. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8
32. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605 (Pubitemid 36857948)
33. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109 (Pubitemid 39331023)
34. Castaneda CA, Gomez HL. Pazopanib: an antiangiogenic drug in perspective. Future Oncol 2009;5:1335-48
35. Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4-[(2,3-dimethyl- 2H-indazol-6-yl)methylamino]-2-pyrimidinyl] amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008;51:4632-40
36. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24 (Pubitemid 46089672)
37. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34 (Pubitemid 46089673)
38. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
39. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52 (Pubitemid 38821812)
40. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-83
41. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 2007;8:975-84 (Pubitemid 47629888)
42. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8
43. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63 (Pubitemid 41079774)
44. Jonasch E, BA, Chen Y, Bair A, et al. Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010;28:abstract TPS235
45. Pfizer announces positive Phase 3 trial results for axitininb in patients with previously-treated metastatic renal cell carcinoma. Available from: www.news-medical.net/news/20101120/Pfizers-Phase-3-AXIS-1032-trial-for- metastatic-renal-cell-carcinoma-meets-primary endpoint. [Last accessed 22 March 2011]
46. Eskens F, dJM, Esteves B, de Jonge M, et al. Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1,-2 and-3 tyrosine kinase inhibitor, in patients with advanced solid tumors [abstract LB-201]. Annual Meeting of the American Association for Cancer Research 2008; 2008
47. Bhargava P, EB, Nosov DA, Esteves B, et al. Updated activity and safety results of a Phase II randomised discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol 2009;27:abstract 5032
48. Bhargava P, EB, Al-Adhami M, Esteves B, et al. Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2010;28:abstract 4599
49. Lee SH, Lopes de Menezes D, Vora J, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11:3633-41 (Pubitemid 40685578)
50. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309 (Pubitemid 41443415)
51. Lopes de Menezes DE, Peng J, Garrett EN, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005;11:5281-91 (Pubitemid 41003717)
52. Sarker D, Molife R, Evans TR, et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008;14:2075-81 (Pubitemid 351551118)
53. Angevin E, LJ, Pande A, Lopez JA, et al. TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study. J Clin Oncol 2009;27:abstract 3563
54. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045-54 (Pubitemid 47218051)
55. Sridhar SS, HS, Mackenzie MJ, Hotte SJ, et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): a trial of the PMH Phase II consortium. J Clin Oncol 2007;25:abstract 5093
56. Mulders P, HR, Nathan P, Hawkins R, et al. Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 2009;7:abstract 49LBA
57. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006;5:995-1006 (Pubitemid 43724600)
58. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2010 [Epub ahead of print]
59. Wong CI, Koh TS, Soo R, et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009;27:4718-26
60. Tannir NM, WY, Kollmannsberger CK, Wong Y, et al. Phase II trial of linifanib in patients with advanced renal cell cancer after sunitinib failure. J Clin Oncol 2010;28:abstract 4527
61. Eisen T, JH, Nathan P, Joensuu H, et al. Phase II trial of the oral multikinase inhibitor BAY 73-4506 as 1st-line therapy in patients with metastatic or unresectable renal cell carcinoma (RCC). Eur J Cancer Suppl 2009b;7:abstract 7.105
62. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81 (Pubitemid 46849157)
63. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
64. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8 (Pubitemid 41161231)
65. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-40 (Pubitemid 46474636)
66. Wang X, Yue P, Chan CB, et al. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 2007;27:7405-13 (Pubitemid 350033648)
67. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30
68. Cho DC, Cohen MB, Panka DJ, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010;16:3628-38
69. Chiorean EG, MD, Harris WB, Mahadevan D, et al. Phase I evaluation of SF1126, a vascular targeted P13K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol 2009;27:abstract 2558
70. Brana I, LP, Baselga J, LoRusso P, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a P13K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010;28:abstract 3030
71. Vjaz A. Phosphatidyl 3-kinase (P13K) inhibitors as anticancer drugs. Drugs Fut 2007;32:537
72. Edelman G, BC, Shapiro G, Bedell C, et al. A phase I dose-escalation study of XL147 (SAR245408), a P13K inhibitor adminstered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010;28:abstract 3004
73. Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2:1093-103
74. Schreeder MT, FR, Stephenson JJ, Figlin RA, et al. Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma. J Clin Oncol 2008;26:abstract 16024
75. Holland WS, MP, Gandara DR, Mack PC, et al. Preclinical rationale for combination targeted therapy in advanced clear cell renal cell carcinoma (RCC): abrogation of rapamycin-mediated induction of AKT phosphorylation by perifosine. J Clin Oncol 2008;26:abstract 16083
76. Crul M, RH, de Klerk GJ, Rosing H, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002;38:1615
77. Van Ummersen L, BK, Volkman J, Binger K, et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patient with advanced cancer. Clin Cancer Res 2004;10:7450
78. Stephenson J, SM, Waples J, Schreeder M, et al. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI). J Clin Oncol 2007;25:abstract 15622
79. Cho DC, FR, Flaherty KT, Figlin RA, et al. A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). J Clin Oncol 2009;27:abstract 5101
80. Tolcher AW, YT, Fearen I, Yap TA, et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti) in patients (pts) with advanced solid tumor (ST). J Clin Oncol 2009;27:abstract 3503
81. Tan DS, DH, Olmos D, Dumez H, et al. First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. J Clin Oncol 2010;28:abstract 3006
82. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800
83. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381-5
84. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75
85. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17 (Pubitemid 30060482)
86. Vogelzang NJ. Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol 2010;28:5017-19
87. Rini BI, Vogelzang NJ, Dumas MC, et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000;18:2419-26 (Pubitemid 30415829)
88. Tannir NM, Thall PF, Ng CS, et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008;180:867-72; discussion 872
89. Waters JS, Moss C, Pyle L, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004;91:1763-8 (Pubitemid 39664962)
90. Stadler WM, Halabi S, Rini B, et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 2006;107:1273-9 (Pubitemid 44452776)
91. Van Veldhuizen PJ, Hussey M, Lara PN Jr, et al. A Phase II study of gemcitabine and capecitabine in patients with advanced renal cell cancer: southwest oncology group study S0312. Am J Clin Oncol 2009 [Epub ahead of print]
92. Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010;11:350-7
93. Richey SL, Ng C, Lim ZD, et al. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2010 [Epub ahead of print]
94. Naito S, Eto M, Shinohara N, et al. Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2010;28:5022-9
95. Naito S, Tsukamoto T, Usami M, et al. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2010;66:1065-70
96. Naito S, Yamamoto N, Takayama T, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010;57:317-25
97. Larkin J, Gore M. Is advanced renal cell carcinoma becoming a chronic disease? Lancet 2010;376:574-5
98. Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70:1063-71
99. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 2007;13:764s-769s
100. Swanton C, Larkin JM, Gerlinger M, et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2010;2:53